about
Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suDose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsPopulation pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.Determinants of child-parent agreement in quality-of-life reports: a European study of children with cerebral palsy.Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma.Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.Parent-reported quality of life of children with cerebral palsy in Europe.Parent and professional reports of the quality of life of children with cerebral palsy and associated intellectual impairment.Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin.Prevalence and Associated Factors of Minor Neuromotor Dysfunctions at Age 5 Years in Prematurely Born ChildrenCancer adolescent pathway in France between 1988 and 1997Psychological problems in children with cerebral palsy: a cross-sectional European studyReliability and validity of the Child Health QuestionnairePF-50 for European children with cerebral palsyPsychological problems in children with hemiplegia: a European multicentre surveyDetermination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding sitePharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients
P50
Q33415594-EE0E8B61-FA4F-46D3-B784-CFADD45AE498Q33416659-375B09DF-3D94-4BFE-AE74-0007330D521DQ36287956-E600337A-3B7E-4F8E-A07F-5CA55F998D59Q37369319-CDD92F65-19A6-4240-9A46-DCC862F3A694Q39631802-7D6AE557-CB40-4002-AB0F-A316431570F9Q44665650-2F72AD3E-5354-473C-8E8D-427419E4AF4CQ45970694-E8320064-EF23-42AE-B2B6-2E3B9178DE88Q46041320-A0FA2F25-DA77-44D0-BF23-A57B69D923CAQ50043715-1E878642-A47F-4D07-929E-66890A91E5A9Q50876985-74FDFA74-7CB1-4D38-BA26-41F49B675002Q53132660-4306790A-E6F7-4A04-9CB6-802AF6C3266BQ54194574-E5A1AE13-A956-4EFA-A5DF-7FAC340D51D1Q61859679-A4644B09-D344-4641-A4D3-9D0D5CC8F40CQ79825060-4C93F9F3-E53A-4D40-A6B7-7C37338A404BQ80203526-FB9F272C-ECE9-4135-8BD6-02081819FFF3Q81327649-96854CF5-FB40-40B3-BCB4-1EDD836D9DC1Q83327462-2E977CB5-2783-46CA-8D66-03A28167F8D1Q86706636-E49532E6-5DE3-4E09-961C-8F07C795083FQ90022471-A71017E2-7EE4-41EF-9463-E82FC6DD1904
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Melanie White-Koning
@ast
Melanie White-Koning
@en
Melanie White-Koning
@es
Melanie White-Koning
@nl
type
label
Melanie White-Koning
@ast
Melanie White-Koning
@en
Melanie White-Koning
@es
Melanie White-Koning
@nl
prefLabel
Melanie White-Koning
@ast
Melanie White-Koning
@en
Melanie White-Koning
@es
Melanie White-Koning
@nl
P1053
J-5039-2014
P106
P31
P496
0000-0001-5072-5489